Publication: 4562

PD-L1 expression and clinical outcomes to cabozantinib, everolimus and sunitinib in patients with metastatic renal cell carcinoma: analysis of the randomized clinical trials METEOR and CABOSUN
      QxMD      Google Scholar   
Citation:
Clin Cancer Res vol 25 (20) 6080-8
Year:
2019
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
2998  
Children:
None
Program:
OGC
Primary Committee:
GU
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U24CA196171 ,  
Corr. Author:
 
Authors:
                                   
Networks:
 
Study
Multiple Studies, or Legacy Studies in Alliance Study:
Alliance-A031203
Phases:
2
Keywords:
Cabozantinib, Sunitinib, Everolimus, PD-L1, renal cell carcinoma, predictive biomarkers